Israel - English - Ministry of Health

abic marketing ltd, israel - modafinil - caplets - modafinil 100 mg - modafinil - to improve wakefulness in patients with excessive sleepiness associated with narcolepsy (with or without cataplexy), obstructive sleep apnea/hypopnea syndrome ( osahs ) and shift work sleep disorder (swds).

Israel - English - Ministry of Health

abic marketing ltd, israel - acitretin - capsules - acitretin 10 mg - acitretin - severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.

Israel - English - Ministry of Health

abic marketing ltd, israel - acitretin - capsules - acitretin 25 mg - acitretin - severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.

Israel - English - Ministry of Health

abic marketing ltd, israel - finasteride - film coated tablets - finasteride 1 mg - finasteride - finasteride - finasteride teva 1 mg is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.

Israel - English - Ministry of Health

abic marketing ltd, israel - metformin hydrochloride; pioglitazone as hydrochloride - film coated tablets - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Israel - English - Ministry of Health

abic marketing ltd, israel - deutetrabenazine - tablets extended release - deutetrabenazine 12 mg - austedo is indicated in adults for the treatment of: • chorea associated with huntington’s disease • tardive dyskinesia

Israel - English - Ministry of Health

abic marketing ltd, israel - deutetrabenazine - tablets extended release - deutetrabenazine 6 mg - austedo is indicated in adults for the treatment of: • chorea associated with huntington’s disease • tardive dyskinesia

Israel - English - Ministry of Health

abic marketing ltd, israel - deutetrabenazine - tablets extended release - deutetrabenazine 9 mg - austedo is indicated in adults for the treatment of: • chorea associated with huntington’s disease • tardive dyskinesia

Israel - English - Ministry of Health

abic marketing ltd, israel - lorcaserin hydrochloride hemihydrate - film coated tablets - lorcaserin hydrochloride hemihydrate 10.4 mg - lorcaserin - belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (bmi) of:• 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)

Israel - English - Ministry of Health

abic marketing ltd, israel - prasugrel as hydrobromide - film coated tablets - prasugrel as hydrobromide 10 mg - prasugrel - prasugrel teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.